Designing and Evaluating Bayesian Advanced Adaptive Randomised Clinical Trials: A Practical Guide
Pharmaceutical Statistics · 2025
DOI: 10.1002/pst.70042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von Anders Granholm und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care 4131, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Research Design, Randomized Controlled Trials as Topic, Adaptive Clinical Trials as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sygeforsikringen 'danmark', The Novo Nordisk Foundation, Grosserer Jakob Ehrenreich og Hustru Grete Ehrenreichs Fond.
Abstract (Originalsprache)
Advanced adaptive randomised clinical trials are increasingly used. Compared to their conventional counterparts, their flexibility may make them more efficient, increase the probability of obtaining conclusive results without larger samples than necessary, and increase the probability that individual participants are allocated to more promising interventions. However, limited guidance is available on designing and evaluating the performance of advanced adaptive trials. Here, we summarise the methodological considerations and provide practical guidance on the entire workflow of planning and evaluating advanced adaptive trials using adaptive stopping, adaptive arm dropping, and response‐adaptive randomisation within a Bayesian statistical framework. This comprehensive practical guide covers the key methodological decisions for Bayesian advanced adaptive trials and their specification and evaluation using statistical simulation. These considerations include interventions and common control use; outcome type and generation; analysis timing and outcome‐data lag; allocation rules; analysis model; adaptation rules for stopping and arm dropping; clinical scenarios assessed; performance metrics; calibration; sensitivity analyses; and reporting. The considerations are covered in the context of realistic examples, along with simulation code using the adaptr R package. In conclusion, this practical guide will help clinical trialists, methodologists, and biostatisticians design and evaluate Bayesian advanced adaptive trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Intensive Care 4131, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Anders Granholm, Aksel Karl Georg Jensen, Theis Lange, Anders Perner, Morten Hylander Møller, Benjamin Skov Kaas-Hansen
Förderung
- Sygeforsikringen 'danmark'
- The Novo Nordisk Foundation
- Grosserer Jakob Ehrenreich og Hustru Grete Ehrenreichs Fond
- Dagmar Marshalls Fond
- Savværksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat
- Danmarks Frie Forskningsfond
Zitieren
APA
Granholm, A., Jensen, A. K. G., Lange, T., Perner, A., Møller, M. H., & Kaas-Hansen, B. S. (2025). Designing and Evaluating Bayesian Advanced Adaptive Randomised Clinical Trials: A Practical Guide. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70042
Vancouver
Granholm A, Jensen AKG, Lange T, Perner A, Møller MH, Kaas-Hansen BS. Designing and Evaluating Bayesian Advanced Adaptive Randomised Clinical Trials: A Practical Guide. Pharmaceutical Statistics. 2025. doi:10.1002/pst.70042
BibTeX
@article{Granholm2025,
author = {Granholm, Anders and Jensen, Aksel Karl Georg and Lange, Theis and Perner, Anders and Møller, Morten Hylander and Kaas-Hansen, Benjamin Skov},
title = {Designing and Evaluating Bayesian Advanced Adaptive Randomised Clinical Trials: A Practical Guide},
journal = {Pharmaceutical Statistics},
year = {2025},
doi = {10.1002/pst.70042}
}
EUVIMED